{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:38:05Z","timestamp":1795221485179,"version":"4.10.3"},"reference-count":142,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with damage to motor neurons and leading to severe muscle weakness and, eventually, death. Over the past decade, understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced. This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy.<\/jats:p>","DOI":"10.3390\/ijms26115240","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:14:27Z","timestamp":1748585667000},"page":"5240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2)"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8172-5374","authenticated-orcid":false,"given":"Christina","family":"Tolochko","sequence":"first","affiliation":[{"name":"V. A. Almazov Federal National Medical Research Centre, Saint Petersburg 197341, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2588-4772","authenticated-orcid":false,"given":"Olga","family":"Shiryaeva","sequence":"additional","affiliation":[{"name":"Research Laboratory of Neurogenesis and Neurodegenerative Diseases, V. A. Almazov Federal National Medical Research Centre, Saint Petersburg 197341, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Alekseeva","sequence":"additional","affiliation":[{"name":"V. A. Almazov Federal National Medical Research Centre, Saint Petersburg 197341, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-7367","authenticated-orcid":false,"given":"Vyacheslav","family":"Dyachuk","sequence":"additional","affiliation":[{"name":"Research Laboratory of Neurogenesis and Neurodegenerative Diseases, V. A. Almazov Federal National Medical Research Centre, Saint Petersburg 197341, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"Hardiman","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature","volume":"41","author":"Logroscino","year":"2013","journal-title":"Neuroepidemiology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kawamoto, T., Ura, M., and Nittono, H. (2015). Intrapersonal and interpersonal processes of social exclusion. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00062"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1093\/brain\/aws144","article-title":"Young-onset amyotrophic lateral sclerosis: Historical and other observations","volume":"135","author":"Turner","year":"2012","journal-title":"Brain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.13015","article-title":"The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis","volume":"92","author":"Liu","year":"2017","journal-title":"Clin. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.17650\/2222-8721-2022-12-3-52-58","article-title":"Juvenile amyotrophic lateral sclerosis type 4: Case report and review","volume":"12","author":"Rudenskaya","year":"2022","journal-title":"Neuromuscul. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrneurol.2013.203","article-title":"The epidemiology of ALS: A conspiracy of genes, environment and time","volume":"9","author":"Hardiman","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaneurol.2019.2044","article-title":"Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis","volume":"76","author":"Ryan","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"fcac145","DOI":"10.1093\/braincomms\/fcac145","article-title":"Prionoids in amyotrophic lateral sclerosis","volume":"4","author":"Gosset","year":"2022","journal-title":"Brain Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s10072-023-06753-5","article-title":"Increasing prevalence 2015\u20132019 of amyotrophic lateral sclerosis in Sardinia, Italy","volume":"44","author":"Pateri","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12408","DOI":"10.1038\/ncomms12408","article-title":"Projected increase in amyotrophic lateral sclerosis from 2015 to 2040","volume":"7","author":"Arthur","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/21678421.2019.1587629","article-title":"Predicting the future of ALS: The impact of demographic change and potential new treatments on the prevalence of ALS in the United Kingdom, 2020\u20132116","volume":"20","author":"Gowland","year":"2019","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1007\/s12035-017-0856-0","article-title":"Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: A Link to Neurodegeneration","volume":"55","author":"Maurel","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneurol.2010.18","article-title":"TAR DNA-binding protein 43 in neurodegenerative disease","volume":"6","author":"Lee","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00401-016-1666-6","article-title":"ALS\/FTLD: Experimental models and reality","volume":"133","author":"Tan","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/nan.12625","article-title":"TDP43 proteinopathy is associated with aberrant DNA methylation in human amyotrophic lateral sclerosis","volume":"47","author":"Schaber","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Koike, Y., Sugai, A., Hara, N., Ito, J., Yokoseki, A., Ishihara, T., Yamagishi, T., Tsuboguchi, S., Tada, M., and Ikeuchi, T. (2021). Age-related demethylation of the TDP-43 autoregulatory region in the human motor cortex. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-02621-0"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pneurobio.2016.05.004","article-title":"ALS: A bucket of genes, environment, metabolism and unknown ingredients","volume":"142","author":"Poza","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuro.2021.09.004","article-title":"Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S","volume":"87","author":"Andrew","year":"2021","journal-title":"Neurotoxicology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Xue, Y.C., Feuer, R., Cashman, N., and Luo, H. (2018). Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis?. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnmol.2018.00063"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","article-title":"Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Arnold, F.J., Putka, A.F., Raychaudhuri, U., Hsu, S., Bedlack, R.S., Bennett, C.L., and La Spada, A.R. (2024). Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115587"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hemerkov\u00e1, P., and Vali\u0161, M. (2021). Role of Oxidative Stress in the Pathogenesis of Amyotrophic Lateral Sclerosis: Antioxidant Metalloenzymes and Therapeutic Strategies. Biomolecules, 11.","DOI":"10.3390\/biom11030437"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Genin, E.C., Abou-Ali, M., and Paquis-Flucklinger, V. (2023). Mitochondria, A Key Target in Amyotrophic Lateral Sclerosis Pathogenesis. Genes, 14.","DOI":"10.3390\/genes14111981"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"De Marchi, F., Franjkic, T., Schito, P., Russo, T., Nimac, J., Chami, A.A., Mele, A., Vidatic, L., Kriz, J., and Julien, J.-P. (2023). Emerging Trends in the Field of Inflammation and Proteinopathy in ALS\/FTD Spectrum Disorder. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061599"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/15548627.2021.1926656","article-title":"Autophagy and ALS: Mechanistic insights and therapeutic implications","volume":"18","author":"Chua","year":"2022","journal-title":"Autophagy"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, J., and Wang, F. (2017). Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01005"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2017.02.004","article-title":"Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?","volume":"105","author":"Hafezparast","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410380114","article-title":"Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2015.09.019","article-title":"Excitotoxicity in ALS: Overstimulation, or overreaction?","volume":"275","author":"King","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3758\/BF03210965","article-title":"Retrieval-induced forgetting in an eyewitness-memory paradigm","volume":"2","author":"Shaw","year":"1995","journal-title":"Psychon. Bull. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/79944","article-title":"OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28","volume":"26","author":"Alexander","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wuolikainen, A., Moritz, T., Marklund, S.L., Antti, H., and Andersen, P.M. (2011). Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC\/TOFMS. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017947"},{"key":"ref_35","first-page":"123","article-title":"In vivo imaging of ferroptosis through nanodynamic changes in lipid membranes","volume":"20","author":"Sonay","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0896-6273(00)80086-0","article-title":"Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate","volume":"16","author":"Rothstein","year":"1996","journal-title":"Neuron"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-55769-4_6","article-title":"EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis","volume":"16","author":"Rosenblum","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pbiomolbio.2003.10.002","article-title":"Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones","volume":"86","author":"Khodorov","year":"2004","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.tins.2021.01.001","article-title":"Excitotoxicity Revisited: Mitochondria on the Verge of a Nervous Breakdown","volume":"44","author":"Plotegher","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/jcbfm.2013.227","article-title":"Activation and regulation of cellular inflammasomes: Gaps in our knowledge for central nervous system injury","volume":"34","author":"Dietrich","year":"2014","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"861231","DOI":"10.1155\/2014\/861231","article-title":"Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity","volume":"2014","author":"Olmos","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jnc.13606","article-title":"In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3","volume":"138","author":"Schmidt","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.9758\/cpn.2019.17.3.438","article-title":"Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes","volume":"17","author":"Sala","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"107986","DOI":"10.1016\/j.neuropharm.2020.107986","article-title":"Disease-modifying therapies in amyotrophic lateral sclerosis","volume":"167","author":"Chio","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.neurol.2020.12.003","article-title":"Therapeutic news in ALS","volume":"177","author":"Corcia","year":"2021","journal-title":"Rev. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-022-01769-1","article-title":"Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents","volume":"82","author":"Johnson","year":"2022","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"946073","DOI":"10.1155\/2014\/946073","article-title":"Partial block by riluzole of muscle sodium channels in myotubes from amyotrophic lateral sclerosis patients","volume":"2014","author":"Deflorio","year":"2014","journal-title":"Neurol. Res. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0014-2999(93)90037-I","article-title":"The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1","volume":"250","author":"Martin","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2018.09.021","article-title":"Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool","volume":"143","author":"Lazarevic","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/B:CEMN.0000012717.37839.07","article-title":"Riluzole enhances glutamate uptake in rat astrocyte cultures","volume":"24","author":"Frizzo","year":"2004","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mignani, S., Majoral, J.P., Desaphy, J.F., and Lentini, G. (2020). From riluzole to dexpramipexole via substituted-benzothiazole derivatives for amyotrophic lateral sclerosis disease treatment: Case studies. Molecules, 25.","DOI":"10.3390\/molecules25153320"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e00029-18","DOI":"10.1128\/MMBR.00029-18","article-title":"Oxidoreductases and Reactive Oxygen Species in Conversion of Lignocellulosic Biomass","volume":"82","author":"Bissaro","year":"2018","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ko, V.I., Ong, K., Cleveland, D.W., Yu, H., and Ravits, J.M. (2024). CK1\u03b4\/\u03b5 kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation. Neurobiol. Dis., 196.","DOI":"10.1016\/j.nbd.2024.106516"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn.2778","article-title":"Characterizing the RNA targets and position-dependent splicing regulation by TDP-43","volume":"14","author":"Tollervey","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1111\/ejn.15422","article-title":"Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis","volume":"54","author":"Wright","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"J. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"VI19","DOI":"10.1007\/PL00007784","article-title":"What has changed with riluzole?","volume":"247","author":"Meininger","year":"2000","journal-title":"J. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/17434470410019898","article-title":"Disease-modifying drug therapies","volume":"5","author":"Brooks","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/146608202317576499","article-title":"Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis","volume":"3","author":"Turner","year":"2002","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14660820500396984","article-title":"Audit of outcomes in motor neuron disease (MND) patients treated with riluzole","volume":"7","author":"Mitchell","year":"2006","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/21678421.2013.763281","article-title":"The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: A population-based study in Modena, Italy","volume":"14","author":"Georgoulopoulou","year":"2013","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/21678421.2016.1195410","article-title":"Prognostic factors and survival of ALS patients from Belgrade, Serbia","volume":"17","author":"Stevic","year":"2016","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1590\/0004-282x20170083","article-title":"Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS","volume":"75","author":"Favero","year":"2017","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","article-title":"Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis","volume":"21","author":"Andrews","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.0000000000000951","article-title":"The PRO-ACT database: Design, initial analyses and predictive features","volume":"83","author":"Atassi","year":"2014","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/21678421.2019.1655060","article-title":"Stage-specific riluzole effect in amyotrophic lateral sclerosis: A retrospective study","volume":"21","author":"Thakore","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/jnnp-2018-320211","article-title":"Evidence for a multimodal effect of riluzole in patients with ALS?","volume":"90","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00415-003-1026-z","article-title":"An outcome study of riluzole in amyotrophic lateral sclerosis\u2014A population-based study in Ireland, 1996\u20132000","volume":"250","author":"Traynor","year":"2003","journal-title":"J. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: A population-based study in southern Italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chen, L., Liu, X., Tang, L., Zhang, N., and Fan, D. (2016). Long-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in China. Front. Aging Neurosci., 8.","DOI":"10.3389\/fnagi.2016.00246"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000369813","article-title":"Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course","volume":"44","author":"Cetin","year":"2015","journal-title":"Neuroepidemiology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00415-018-8778-y","article-title":"Riluzole and other prognostic factors in ALS: A population-based registry study in Italy","volume":"265","author":"Mandrioli","year":"2018","journal-title":"J. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/146608201753275508","article-title":"The Rilutek (riluzole) Global Early Access Programme: An open-label safety evaluation in the treatment of amyotrophic lateral sclerosis","volume":"2","author":"Debove","year":"2001","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mus.27541","article-title":"Ten years of riluzole use in a tertiary ALS clinic","volume":"65","author":"Geronimo","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/106002809703100614","article-title":"Riluzole: A new agent for amyotrophic lateral sclerosis","volume":"31","author":"Wagner","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/01.WNL.0000123015.48097.9A","article-title":"Riluzole-induced neutropenia","volume":"62","author":"Weber","year":"2004","journal-title":"Neurology"},{"key":"ref_81","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: Double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MCG.0000000000000063","article-title":"Moderately severe acute pancreatitis associated with riluzole","volume":"48","author":"Ianiro","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2001.03982.x","article-title":"Riluzole-induced acute pancreatitis","volume":"96","author":"Rodrigo","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1212\/WNL.52.4.892","article-title":"Riluzole-induced pancreatitis","volume":"52","author":"Drory","year":"1999","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jocn.2017.08.032","article-title":"Riluzole-induced recurrent pancreatitis","volume":"45","year":"2017","journal-title":"J. Clin. Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1212\/WNL.94.15_supplement.4121","article-title":"Early Treatment Effects of Riluzole in ALS: Isometric Strength Improvement in Sentinel Muscles Correlates with Improved Survival (4121)","volume":"94","author":"Brooks","year":"2020","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Onesti, E., Schettino, I., Gori, M.C., Frasca, V., Ceccanti, M., Cambieri, C., Ruoppolo, G., and Inghilleri, M. (2017). Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00094"},{"key":"ref_88","first-page":"61","article-title":"Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis","volume":"7","author":"Hinchcliffe","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.clinthera.2019.09.016","article-title":"Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration","volume":"41","author":"Brooks","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Akamatsu, M., Yamashita, T., Hirose, N., Teramoto, S., and Kwak, S. (2016). The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep., 6.","DOI":"10.1038\/srep28649"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10072-022-05867-6","article-title":"Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"43","author":"Turalde","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and Efficacy of Ceftriaxone for Amyotrophic Lateral Sclerosis: A Multi-Stage, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_94","first-page":"5021694","article-title":"Oxidative stress in amyotrophic lateral sclerosis: Pathophysiology and opportunities for pharmacological intervention","volume":"2020","author":"Montezinho","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8416763","DOI":"10.1155\/2017\/8416763","article-title":"Oxidative stress: Harms and benefits for human health","volume":"2017","author":"Pizzino","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Carr\u00ec, M.T., Valle, C., Bozzo, F., and Cozzolino, M. (2015). Oxidative stress and mitochondrial damage: Importance in non-SOD1 ALS. Front. Cell Neurosci., 9.","DOI":"10.3389\/fncel.2015.00041"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"132933","DOI":"10.1016\/j.neulet.2017.06.052","article-title":"The role of mitochondria in amyotrophic lateral sclerosis","volume":"710","author":"Smith","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuint.2008.01.009","article-title":"Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease","volume":"52","author":"Babu","year":"2008","journal-title":"Neurochem. Int."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kim, K. (2021). Glutathione in the nervous system as a potential therapeutic target to control the development and progression of amyotrophic lateral sclerosis. Antioxidants, 10.","DOI":"10.3390\/antiox10071011"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.freeradbiomed.2021.07.022","article-title":"NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS","volume":"173","author":"Ferraiuolo","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0304-3940(95)12039-7","article-title":"Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis","volume":"199","author":"Abe","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1046\/j.1471-4159.1997.69052064.x","article-title":"Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis","volume":"69","author":"Ferrante","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.freeradbiomed.2009.11.018","article-title":"Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target","volume":"48","author":"Barber","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Edaravone Acute Infarction Study Group (2003). Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis., 15, 222\u2013229.","DOI":"10.1159\/000069318"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2176\/nmc.ra.2014-0219","article-title":"Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: Subanalysis of RESCUE-Japan registry","volume":"55","author":"Miyaji","year":"2015","journal-title":"Neurol. Med. Chir."},{"key":"ref_107","first-page":"25","article-title":"Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_108","unstructured":"Writing Group, Edaravone (MCI-186) ALS 19 Study Group (2017). Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol., 16, 505\u2013512."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"J. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101590","DOI":"10.1016\/j.eclinm.2022.101590","article-title":"Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis","volume":"52","author":"Brooks","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e2014645","DOI":"10.1001\/jamanetworkopen.2020.14645","article-title":"Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System","volume":"3","author":"Vu","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_113","first-page":"e27337","article-title":"The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes","volume":"14","author":"Jayasinghe","year":"2022","journal-title":"Cureus"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"44","author":"Nourelden","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Shang, Q., Zhou, J., Ye, J., and Chen, M. (2025). Adverse events reporting of edaravone: A real-world analysis from FAERS database. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-92605-5"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cpdd.952","article-title":"Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_117","unstructured":"(2024, January 15). Reports Top-Line Results from Phase 3 ADORE Study in ALS. News Release. Ferrer. Published 10 January 2024. Available online: https:\/\/www.ferrer.com\/en\/results-study-ADORE-ALS."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Robinson, A.P., Zhang, J.Z., Titus, H.E., Karl, M., Merzliakov, M., Dorfman, A.R., Karlik, S., Stewart, M.G., Watt, R.K., and Facer, B.D. (2020). Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-58709-w"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"102036","DOI":"10.1016\/j.eclinm.2023.102036","article-title":"Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): A phase 2, randomised, double-blind, placebo-controlled trial and open label extension","volume":"60","author":"Vucic","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_120","unstructured":"Cudkowicz, M.E. (2021). NCT04297683: HEALEY ALS Platform Trial\u2014Master Protocol, ClinicalTrials.gov."},{"key":"ref_121","unstructured":"Cudkowicz, M.E. (2021). NCT04414345: HEALEY ALS Platform Trial\u2014Regimen C CNM-Au8, ClinicalTrials.gov."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS","volume":"69","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.06.022","article-title":"Tauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress","volume":"397","author":"Lee","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s42269-019-0089-7","article-title":"Potential prophylactic effect of chemical chaperones for alleviation of endoplasmic reticulum stress in experimental diabetic cataract","volume":"43","author":"Elhossary","year":"2019","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40035-022-00307-z","article-title":"Tauroursodeoxycholic acid: A potential therapeutic tool in neurodegenerative diseases","volume":"11","author":"Khalaf","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03401914","article-title":"Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production","volume":"4","author":"Rodrigues","year":"1998","journal-title":"Mol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1172\/JCI1325","article-title":"A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation","volume":"101","author":"Rodrigues","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.cdd.4400560","article-title":"Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation","volume":"6","author":"Rodrigues","year":"1999","journal-title":"Cell Death Differ."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"G327","DOI":"10.1152\/ajpgi.00093.2007","article-title":"Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes","volume":"293","author":"Castro","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"102256","DOI":"10.1016\/j.eclinm.2023.102256","article-title":"Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: A retrospective population-based cohort study","volume":"65","author":"Zucchi","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nature13151","article-title":"Origins and functional evolution of Y chromosomes across mammals","volume":"508","author":"Cortez","year":"2014","journal-title":"Nature"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"Ryu","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.27091","article-title":"Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis","volume":"63","author":"Paganoni","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Lin, T.J., Cheng, G.C., Wu, L.Y., Lai, W.Y., Ling, T.Y., Kuo, Y.C., and Huang, Y.H. (2022). Potential of cellular therapy for ALS: Current strategies and future prospects. Front. Cell Dev. Biol., 10, Erratum in Front. Cell Dev. Biol.\u00a02023, 11, 1292681. https:\/\/doi.org\/10.3389\/fcell.2023.1292681.","DOI":"10.3389\/fcell.2022.851613"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Shiryaeva, O., Tolochko, C., Alekseeva, T., and Dyachuk, V. (2025). Targets and gene therapy of ALS (Part 1). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094063"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40035-023-00380-y","article-title":"Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis","volume":"12","author":"Richardson","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Liu, M.L., Ma, S., Tai, W., Zhong, X., Ni, H., Zou, Y., Wang, J., and Zhang, C.-L. (2023). Chemical screens in aging-relevant human motor neurons identify MAP4Ks as therapeutic targets for amyotrophic lateral sclerosis. bioRxiv.","DOI":"10.1101\/2023.04.24.538014"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.4103\/1673-5374.389639","article-title":"MAP4K inhibition as a potential therapy for amyotrophic lateral sclerosis","volume":"19","author":"Ma","year":"2024","journal-title":"Neural. Regen. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41419-023-06395-7","article-title":"Screens in aging-relevant human ALS-motor neurons identify MAP4Ks as therapeutic targets for the disease","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:26Z","timestamp":1760031806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":142,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115240"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115240","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}